This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Presentation of 1-year IVAN and 2-year CATT study results

April 18th, 2012

Rockville, Md.: ARVO is pleased to host a presentation of the one-year results from the U.K.'s Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) study and the two-year results of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) trial.

These two multicenter randomized clinical trials, sponsored by the National Institute of Health Research in the United Kingdom and the National Eye Institute, respectively, evaluate the relative efficacy and safety of Lucentis and Avastin in the management of neovascular age-related macular degeneration (AMD).

The presentation will also live-streamed at http://prolibraries.com/arvo/registration/event. While annual meeting registration is required for the session in Fort Lauderdale, the online is event is free.

The 2012 ARVO Annual Meeting, Translational Research: Seeing the Possibilities, takes place May 6 – 10 in Fort Lauderdale, Fla. Registration information can be found at www.arvo.org/am.

Provided by Association for Research in Vision and Ophthalmology

Citation: Presentation of 1-year IVAN and 2-year CATT study results (2012, April 18) retrieved 10 May 2024 from https://sciencex.com/wire-news/96215656/presentation-of-1-year-ivan-and-2-year-catt-study-results.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.